VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

NCT02898753 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Company closure due to lack of funding

Conditions

Pompe Disease

Interventions

DRUG: VAL-1221
DRUG: RhGAA

Sponsor

Valerion Therapeutics, LLC